SCHEMBL5361193

SCHEMBL5361193

Cc1cc(C=C2C(=O)Nc3ccc(I)cc32)cc(C(C)(C)C)c1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 6/20 0.63
EGFR P00533 5/20 0.63
RAF1 P04049 3/20 0.63
MAP1LC3B Q9GZQ8 3/20 0.63
MAPT P10636 3/20 0.63
NTRK1 P04629 1/20 0.63
ARAF P10398 1/20 0.63
PIM1 P11309 1/20 0.63
BRAF P15056 1/20 0.63
CSNK2A1 P68400 1/20 0.63
PIM3 Q86V86 1/20 0.63
SIRT2 Q8IXJ6 1/20 0.63
SIRT1 Q96EB6 1/20 0.63
MYOC Q99972 1/20 0.63
DYRK4 Q9NR20 1/20 0.63
SIRT3 Q9NTG7 1/20 0.63
SIRT5 Q9NXA8 1/20 0.63
MAP3K20 Q9NYL2 1/20 0.63
PIM2 Q9P1W9 1/20 0.63
RIPK3 Q9Y572 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367163 0.88 RAF1 (0.79) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL5367150 0.88 RAF1 (0.61) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL13838786 0.84 RAF1 (0.65) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL7319107 0.82 ERBB2 (0.73) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL7319104 0.82 ERBB2 (0.73) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL5364476 0.82 ERBB2 (0.57) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL6690796 0.82 RAF1 (0.76) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL5369480 0.81 ERBB2 (0.56) ERBB2EGFRRAF1NTRK1IGF1R
SCHEMBL7140867 0.80 RAF1 (0.76) ERBB2EGFRRAF1MAP1LC3BMAPT
SCHEMBL5468784 0.79 LRRK2 (0.72) ERBB2EGFRIGF1RLRRK2CTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885RAF1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.